Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 1519 Carboplatin 1420 Cyclophosphamide 1362 Gemcitabine 1235 Bevacizumab 1226 Paclitaxel 1214 Radiotherapy 1176 Docetaxel 1080 pembrolizumab 1029 Oxaliplatin 936 Capecitabine 902 Fluorouracil 833 Rituximab 729 Doxorubicin 684 Nivolumab 679 Dexamethasone 667 Etoposide 660 Irinotecan 622 Leucovorin 576 Pemetrexed 510 Drug Therapy 493 Cetuximab 483 Trastuzumab 470 Cytarabine 467 Magnetic Resonance Spectroscopy 461 Filgrastim 446 Prednisone 433 Specimen Handling 411 Lenalidomide 410 Vincristine 400

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Interventional × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡